AG
ABEO icon

Aperio Group’s Abeona Therapeutics ABEO Stock Holding History

Aperio Group’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-552
Closed -$29K – 2336
2020
Q1 		$29K Sell
552
-153
-22% -$10.2K ﹤0.01% 2296
2019
Q4 		$58K Buy
705
+172
+32% +$12.1K ﹤0.01% 2291
2019
Q3 		$30K Buy
533
+528
+10,560% +$39.5K ﹤0.01% 2293
2019
Q2 		$1K Buy
+5
New +$838 ﹤0.01% 2967

Other funds holding ABEO

GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Aperio Group's ABEO Position: Q2 2020 in Review

Aperio Group sold out of Abeona Therapeutics (ABEO) in Q2 2020, closing a stake of 552 shares — an estimated $29K sold.

Aperio Group first reported a position in ABEO in Q2 2019 and held it in 4 quarters. The position peaked at $58K in Q4 2019. 83 funds tracked by Wall St. Rank hold ABEO as of Q2 2020.

  • Aperio Group reported no remaining Abeona Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Aperio Group sold 552 Abeona Therapeutics shares in Q2 2020, an estimated $29K.
  • Aperio Group first reported a position in Abeona Therapeutics in Q2 2019 and held it in 4 quarters.
  • Aperio Group's Abeona Therapeutics position peaked at $58K in Q4 2019.
  • 83 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2020.

Based on Aperio Group's 13F filing for Q2 2020, filed 13 Aug 2020.